Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study

Journal of Urology

Volumn 177, Issue 4, 2007, Pages 1307-1312

  Graff, Julie N ^a,b   Mori, Motomi ^c   Li, Hong ^c   Garzotto, Mark ^b,d   Penson, David ^e   Potosky, Arnold L ^f   Beer, Tomasz M ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Biostatistics Shared Resource   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

androgen antagonists; mortality; nomograms; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COMORBIDITY; CONFIDENCE INTERVAL; DEMOGRAPHY; DIGITAL RECTAL EXAMINATION; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ORCHIECTOMY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33947224552     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.11.054     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106
2. Scardino P. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Canc Netw 3 suppl. (2005) S29
3. Harlan L.C., Potosky A., Gilliland F.D., Hoffman R., Albertsen P.C., Hamilton A.S., et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93 (2001) 1864
4. Hellerstedt B.A., and Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52 (2002) 154
5. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295
6. Lawton C.A., Winter K., Murray K., Machtay M., Mesic J.B., Hanks G.E., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937
7. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
8. Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90 (2002) 561
9. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., and Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 (2005) 1615
10. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981
11. Kawakami J., Cowan J.E., Elkin E.P., Latini D.M., DuChane J., and Carroll P.R. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 106 (2006) 1708
12. Janoff D.M., Peterson C., Mongoue-Tchokote S., Peters L., Beer T.M., Wersinger E.M., et al. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int 96 (2005) 503
13. Potosky A.L., Harlan L.C., Stanford J.L., Gilliland F.D., Hamilton A.S., Albertsen P.C., et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 91 (1999) 1719
14. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
15. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977
16. Johansson J.E., Adami H.O., Andersson S.O., Bergstrom R., Holmberg L., and Krusemo U.B. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267 (1992) 2191
17. Penson D.F., Albertsen P.C., Nelson P.S., Barry M., and Stanford J.L. Determining cause of death in prostate cancer: are death certificates valid?. J Natl Cancer Inst 93 (2001) 1822
18. Potosky A.L., Reeve B.B., Clegg L.X., Hoffman R.M., Stephenson R.A., Albertsen P.C., et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94 (2002) 430
19. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
20. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 (2000) 1743